当前位置:首页 >> 资料下载 >> Targeting HSP90 dimerization via theC terminus is effective in imatinib-resistant
提供商
上海协烁仪器科技有限公司资料大小
2.3MB资料图片
下载次数
0次资料类型
PDF 文件浏览次数
243次Heat shock protein 90 (HSP90) stabilizes many client proteins, including the BCR-ABL1
oncoprotein. BCR-ABL1 is the hallmark of chronic myeloid leukemia (CML) in which
treatment-free remission (TFR) is limited, with clinical and economic consequences. Thus,
there is an urgent need for novel therapeutics that synergize with current treatment
approaches. Several inhibitors targeting the N-terminal domain of HSP90 are under investigation, but side effects such as induction of the heat shock response (HSR) and toxicity
have so far precluded their US Food and Drug Administration approval. We have developed a novel inhibitor (aminoxyrone [AX]) of HSP90 function by targeting HSP90 dimerization via the C-terminal domain.
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。